0
Abstract: Poster Presentations |

ERLOTINIB (TARCEVA) EXPERIENCE IN A PUBLIC HEALTH SYSTEM, MINORITY PATIENT POPULATION WITH PROGRESSIVE METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) FREE TO VIEW

Sunita Nathan, MD*; Pritesh Patel, MD; Jennifer Sharma, MD; Joyce Samuel, MD; John H. Stroger, Jr.
Author and Funding Information

Hospital of Cook County, Chicago, IL


Chest


Chest. 2007;132(4_MeetingAbstracts):588b-589. doi:10.1378/chest.132.4_MeetingAbstracts.588b
Text Size: A A A
Published online

Abstract

PURPOSE: Erlotinib is a tyrosine kinase inhibitor used as second and third-line therapy in patients with metastatic NSCLC (mNSCLC). We report our experience with erlotinib use in a minority patient population.

METHODS: Data from 33 patients with mNSCLC treated at Cook County Hospital, Chicago, Illinois over a 2 year period were collected. Demographics, pathology of primary disease, indication for erlotinib, tolerability and response were analyzed.

RESULTS: 33 patients (average age 60.1 yrs, range 31-73 yrs) were identified and analyzed as a retrospective cohort. 54.5% were African American (AA), 3% Caucasian, 18.2% Hispanic, 21.2% Eastern European, and 3% Asian. 78.8% of patients were smokers. 21.2% were non-smokers, who were all non-AA. 87.9% of pts had failed a previous platinum-based regimen. Erlotinib was used as first line treatment in 12.1%, due to refusal of chemotherapy or poor performance status. 21 (63.6%) pts had erlotinib-related toxicities including skin rash, diarrhea and nausea. Erlotinib dose was reduced in 3 pts and discontinued in 3 pts due to toxicities. AA pts were significantly older than non-AA pts (63.4 vs 51.4 p=0.04). Average duration of response (DOR) was 3.5 months (m); Range 2 weeks (wks) to 20m [AA 2.36m; Range 2wks to 7m, non-AA 4.87m; Range 2wks to 20m]. Non-AA pts trended towards a longer DOR than AA pts (4.87m vs 2.36m, p=0.08). DOR was comparable in AA male and AA female pts (2.29m vs 2.55m) and slightly improved in non-AA females than non-AA males (5.3m vs 4m).

CONCLUSION: In this primarily minority-based cohort AA pts were generally older with a shorter DOR than the non-AA pts. This could be due to the non-AA cohort having a higher percent of non-smokers and probably more responsive to biologic agents. Overall erlotinib was well tolerated. Since the number of patients is small, definitive conclusions in either cohort cannot be made. Further investigation in minority patients is warranted.

CLINICAL IMPLICATIONS: Erlotinib could have favorable response in non-smoker, non-AA pts with mNSCLC as a second or third-line therapy.

DISCLOSURE: Sunita Nathan, No Financial Disclosure Information; No Product/Research Disclosure Information

Wednesday, October 24, 2007

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543